

Evaluation Report for Category B, Subcategories B.2.1, 2.3, 2.4, 2.6 Application

Application Number: 2023-6568
Application: New Manufacturing Concentrate (Product Chemistry) – Guarantee; Identity of Formulants; Proportion of Formulants; New combination of Technical Grade Active Ingredients
Applicant: Bayer CropScience Inc.
Product: ACCELERON PRIME MUP
Registration Number: 35423
Active ingredients (a.i.): Fluoxastrobin, metalaxyl, prothioconazole
PMRA Document Number: 3669646

Purpose of Application

The purpose of this application was to register ACCELERON PRIME MUP, a new manufacturing concentrate product.

Chemistry Assessment

ACCELERON PRIME MUP is formulated as a suspension containing fluoxastrobin at a concentration of 50.0 g/L, metalaxyl at a concentration of 100.0 g/L and prothioconazole at a concentration of 50.0 g/L. This product has a density of 1.08-1.12 g/mL and pH of 6.5-7.5. The required chemistry data for ACCELERON PRIME MUP have been provided, reviewed and found to be acceptable.

Health Assessments

ACCELERON PRIME MUP is of low acute toxicity via the oral, dermal and inhalation routes. It is non-irritating to the eyes and non-irritating to the skin and is not a dermal sensitizer.

Occupational and dietary exposure assessments were not required for this application.

Environmental and Value Assessments

Environmental and value assessments were not required for this application.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information acceptable to support the registration of ACCELERON PRIME MUP.

References

PMRA Document Number	Reference
3527039	2023, Acceleron 26FO Fungicide Seed Treatment: Quantities of raw materials (formulants) used in the formulating process, DACO: 3.2.1,3.2.2 CBI
3527040	2023, Product chemistry data to support the registration of Acceleron 26FO fungicide seed treatment product (product identity and composition), DACO: 3.2.1, 3.2.2, 3.2.3, 3.3.1 CBI
3527041	2023, Determination of fluoxastrobin, metalaxyl, and prothioconazole in formulations - HPLC, DACO: 3.4.1 CBI
3527042	2023, Validation of the analytical method AM250823LP3 for the determination of fluoxastrobin, metalaxyl, and prothioconazole in FXA+MTL+PTZ FS 200, specification 102000059553, DACO: 3.4.1 CBI
3527043	2023, Determination of physical chemical properties and accelerated storage stability study on FXA+MTL+PTZ FS 200, DACO: 3.5.1, 3.5.10, 3.5.11, 3.5.12, 3.5.13, 3.5.14, 3.5.15, 3.5.2, 3.5.3, 3.5.6, 3.5.7, 3.5.8, 3.5.9 CBI
3527044	2023, Fluoxastrobin + metalaxyl + prothioconazole FS 200 (50 + 100 + 50 g/L):Acute Oral Toxicity - Up-And-Down Procedure in Rats, DACO 4.6.1
3527045	2023, Waiver for an acute dermal toxicity study on the mixture formulation fluoxastrobin + metalaxyl + prothioconazole FS 200, DACO 4.6.2
3527046	2023, Fluoxastrobin + metalaxyl + prothioconazole FS 200 (50 + 100 + 50 g/L): Acute Inhalation Toxicity in Rats, DACO 4.6.3
3527047	2023, Fluoxastrobin + metalaxyl + prothioconazole FS 200 (50 + 100 + 50 g/L): Primary Eye Irritation in Rabbits, DACO 4.6.4
3527048	2023, Fluoxastrobin + metalaxyl + prothioconazole FS 200 (50 + 100 + 50 g/L): Primary Skin Irritation in Rabbits, DACO 4.6.5
3527049	2023, Fluoxastrobin + metalaxyl + prothioconazole FS 200 (50 + 100 + 50 g/L): Local Lymph Node Assay (LLNA) in Mice, DACO 4.6.6

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2025

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.